Евразийский консенсус ревматологов по диагностике и лечению системной красной волчанки

Группой ведущих ревматологов стран СНГ подготовлены клинические рекомендации по диагностике, лечению и мониторингу системной красной волчанки. Клинические рекомендации подготовлены с учетом рекомендаций национальных ассоциаций ревматологов стран СНГ, международных рекомендаций Европейского альянса ассоциаций ревматологов и Американской коллегии ревматологов. Данные рекомендации предназначены для широкого круга специалистов стран СНГ, ревматологов, терапевтов.

1. Nandakumar KS, Nündel K. Editorial: Systemic lupus erythematosus – predisposition factors, pathogenesis, diagnosis, treatment and disease models. Front Immunol. 2022;13:1118180. doi: 10.3389/fimmu.2022.1118180

2. Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021;11(7):928. doi: 10.3390/biom11070928

3. Kiriakidou M, Ching C. Systemic lupus erythematosus. Ann Intern Med. 2020;172:81-96. doi: 10.7326/AITC202006020

4. lsen NJ, Karp DR. Autoantibodies and SLE: The threshold for disease. Nat Rev Rheumatol. 2014;10:181-186. doi: 10.1038/nrrheum.2013.184

5. Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, et al. Prevalence of systemic lupus erythematosus in the United States: Estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021;73(6):991-996. doi: 10.1002/art.41632

6. Nasonov E, Soloviev S, Davidson JE, Lila A, Togizbayev G, Ivanova R, et al. Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: Data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE). Lupus Sci Med. 2015;2(1):e000060. doi: 10.1136/lupus-2014-000060

7. Nasonov E, Soloviev S, Davidson JE, Lila A, Togizbayev G, Ivanova R, et al. Systemic lupus erythematosus and associated healthcare resource consumption in selected cities from the Russian Federation, Republic of Kazakhstan and Ukraine: The ESSENCE study. J Med Econ. 2018;21(10):1006-1015. doi: 10.1080/13696998.2018.1499518

8. Siegel CH, Sammaritano LR. Systemic lupus erythematosus: A review. JAMA. 2024;331(17):1480-1491. doi: 10.1001/jama.2024.2315

9. Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. Lancet. 2024;403(10441):2326-2338. doi: 10.1016/S0140-6736(24)00398-2

10. Cervera R. Systemic lupus erythematosus criteria nowadays. Med Clin (Barc). 2022;159(4):187-188. doi: 10.1016/j.medcli.2022.04.002

11. Системная красная волчанка: клинические рекомендации. М.;2025. URL: https://cr.minzdrav.gov.ru/viewcr/484_2 (Accessed: 27 November 2025).

12. Lindblom J, Mohan C, Parodis I. Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: Current insights. Curr Opin Rheumatol. 2022;34(2):139-149. doi: 10.1097/BOR.0000000000000862

13. Chitpet P, Chaiamnuay S, Narongroeknawin P, Asavatanabodee P, Leosuthamas P, Pakchotanon R. The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual. Int J Rheum Dis. 2023;26(12):2509- 2516. doi: 10.1111/1756-185X.14949

14. Banjari M, Touma Z, Gladman DD. Improving measures of disease activity in systemic lupus erythematosus. Expert Rev Clin Immunol. 2023;19(2):193-202. doi: 10.1080/1744666X.2023.2156339

15. Kapsala N, Nikolopoulos D, Flouda S, Chavatza A, Tseronis D, Aggelakos M, et al. First diagnosis of systemic lupus erythematosus in hospitalized patients: Clinical phenotypes and pitfalls for the non-specialist. Am J Med. 2022;135(2):244-253.e3. doi: 10.1016/j.amjmed.2021.07.015

16. Bane S, Falasinnu T, Espinosa PR, Simard JF. Misdiagnosis, missed diagnosis, and delayed diagnosis of lupus: A qualitative study of rheumatologists. Arthritis Care Res (Hoboken). 2024;76(11):1566-1573. doi: 10.1002/acr.25405

17. Stull C, Sprow G, Werth VP. Cutaneous involvement in systemic lupus erythematosus: A review for the rheumatologist. J Rheumatol. 2023;50(1):27-35. doi: 10.3899/jrheum.220089

18. Jarukitsopa S, Hoganson DD, Crowson CS, Sokumbi O, Davis MD, Michet CJ Jr, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res (Hoboken). 2015;67(6):817-828. doi: 10.1002/acr.22502

19. Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;48:14-19. doi: 10.1016/j.jaut.2014.01.021

20. Smiljanić Tomičević L, Barešić M, Mayer M, Anić B. Musculoskeletal manifestations of systemic lupus erythematosus. Acta Clin Croat. 2023;62(4):714-723. doi: 10.20471/acc.2023.62.04.18

21. Grossman JM. Lupus arthritis. Best Pract Res Clin Rheumatol. 2009;23(4):495-506. doi: 10.1016/j.berh.2009.04.003

22. Ozbek S, Sert M, Paydas S, Soy M. Delay in the diagnosis of SLE: The importance of arthritis/arthralgia as the initial symptom. Acta Med Okayama. 2003;57(4):187-190. doi: 10.18926/AMO/32807

23. Ball EMA, Bell AL. Lupus arthritis – do we have a clinically useful classification? Rheumatology (Oxford). 2012;51(5):771-779. doi: 10.1093/rheumatology/ker381

24. Pego-Reigosa JM, Cobo-Ibáñez T, Calvo-Alén J, Loza-Santamaría E, Rahman A, Muñoz-Fernández S, et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: A systematic review. Arthritis Care Res (Hoboken). 2013;65(11):1775-1185. doi: 10.1002/acr.22035

25. Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol. 1998;25(2):243-246.

26. Aguilera-Pickens G, Abud-Mendoza C. Pulmonary manifestations in systemic lupus erythematosus: Pleural involvement, acute pneumonitis, chronic interstitial lung disease and diffuse alveolar hemorrhage. Reumatol Clin (Engl Ed). 2018;14(5):294-300. doi: 10.1016/j.reuma.2018.03.012

27. Bendstrup E, Lynn E, Troldborg A. Systemic lupus erythematosusrelated lung disease. Semin Respir Crit Care Med. 2024;45(3):386- 396. doi: 10.1055/s-0044-1782653

28. Piga M, Parodis I, Touma Z, Legge A, Ugarte-Gil MF, Hmamouchi I, et al. Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: Consensus statements from an international task force. Autoimmun Rev. 2025;24(5):103773. doi: 10.1016/j.autrev.2025.103773

29. Nikolopoulos D, Lourenço MH, Depascale R, Triantafyllias K, Parodis I. Evolving concepts in treat-to-target strategies for systemic lupus erythematosus. Mediterr J Rheumatol. 2024;35(Suppl 2):328-341. doi: 10.31138/mjr.290424.eci

30. González-García A, Cusácovich I, Ruiz-Irastorza G. Treatment of systemic lupus erythematosus: New therapeutic options. Rev Clin Esp (Barc). 2023;223(10):629-639. doi: 10.1016/j.rceng.2023.11.001

31. Porta S, Danza A, Arias Saavedra M, Carlomagno A, Goizueta MC, Vivero F, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues. J Clin Med. 2020;9:2709. doi: 10.3390/jcm9092709

32. Apostolopoulos D, Morand EF. It hasn’t gone away: The problem of glucocorticoid use in lupus remains. Rheumatology (Oxford). 2017;56:114-122. doi: 10.1093/rheumatology/kew406

33. Amissah-Arthur MB, Gordon C. Contemporary treatment of systemic lupus erythematosus: An update for clinicians. Ther Adv Chronic Dis. 2010;1:163-175. doi: 10.1177/2040622310380100

34. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762

35. Fanouriakis A, Kostopoulou M, Anders HJ, Andersen J, Aringer M, Beresford MW, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. 2026;85(1):75-90. doi: 10.1016/j.ard.2025.09.007

36. Huang WN, Chen MH, Hsieh SC, Lu LY, Wu YJ, Tsai CY, et al. The Taiwan College of Rheumatology consensus for the management of systemic lupus erythematosus. Int J Rheum Dis. 2026;29(1):e70530. doi: 10.1111/1756-185x.70530

37. Primo-Gabriel C, García-Gómez C, Calvo-Alén J. Systematic literature review of intravenous immunoglobulin use in non-renal and non-hematologic systemic lupus erytehmatosus. Lupus. 2025;34(3):261-269. doi: 10.1177/09612033251319402

38. Насонов ЕЛ, Решетняк TM, Бекетова ТВ, Сукмарова ЗН, Старкова АС. Внутривенный иммуноглобулин в ревматологии: новые данные и проект клинических рекомендаций. Научно-практическая ревматология. 2025;63(6):559-575. doi: 10.47360/1995-4484-2025-559-575

39. Huang J, Fan W, Chen X, Wu S, Dong Z, Zhang Y, et al. Case report: Rituximab combined with plasma exchange treatment for systemic lupus erythematosus complicated with thrombotic microangiopathy and non-cirrhotic portal hypertension. Front Immunol. 2025;15:1475303. doi: 10.3389/fimmu.2024.1475303

40. Kagitani M, Fujiki Y, Suzuka T, Ooe K, Sakamoto A, Takeuchi T, et al. A successful plasma exchange in bridging to rituximab for severe neuropsychiatric lupus and lupus nephritis with viral infections and aspiration pneumonia. Mod Rheumatol Case Rep. 2024;8(2):276-279. doi: 10.1093/mrcr/rxad069

41. Sammaritano LR, Askanase A, Bermas BL, Dall’Era M, DuarteGarcía A, Hiraki LT, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2025;77(9):1045-1065. doi: 10.1002/acr.25528

42. Papachristos DA, Oon S, Hanly JG, Nikpour M. Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: systematic review. Semin Arthritis Rheum. 2021;51(1):49-71. doi: 10.1016/j.semarthrit.2020.12.004

43. Magro-Checa C, Zirkzee EJ, Huizinga TW, Steup-Beekman GM. Management of neuropsychiatric systemic lupus erythematosus: Current approaches and future perspectives. Drugs. 2016;76(4):459- 483. doi: 10.1007/s40265-015-0534-3

44. Лисицына ТА, Вельтищев ДЮ, Серавина ОФ, Ковалевская ОВ, Марченко АС, Насонов ЕЛ. Варианты психических нарушений у больных системной красной волчанкой. Научно-практическая ревматология. 2008;46(4):21-26. doi: 10.14412/1995-4484-2008-531

45. Шалыгина МВ, Попкова ТВ, Волков АВ, Кириллова ИГ. Ранний предиктор высокого сердечно-сосудистого риска при системной красной волчанке. Научно-практическая ревматология. 2025;63(6):604-610. doi: 10.47360/1995-4484-2025-604-610

46. Насонов ЕЛ, Соловьев СК, Аршинов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi: 10.47360/1995-4484-2022-397-41

47. Cheldieva FA, Reshetnyak TM, Shumilova AA, Nurbaeva KS, Cherkasova MV, Lila AM, et al. Global Antiphospholipid Syndrome Score (GAPSS) in patients with systemic lupus erythematosus. Dokl Biochem Biophys. 2023;511(1):227-234. doi: 10.1134/S160767292370028X

48. Frostegård J. Systemic lupus erythematosus and cardiovascular disease. J Intern Med. 2023;293(1):48-62. doi: 10.1111/joim.13557

49. Giannakaki AG, Giannakaki MN, Bothou A, Nikolettos K, Machairiotis N, Pappa KI, et al. Current approaches to the management of rheumatic diseases in pregnancy: Risk stratification, therapeutic advances, and maternal-fetal outcomes. J Pers Med. 2025;15(9):406. doi: 10.3390/jpm15090406

50. McDonald EG, Bissonette L, Ensworth S, Dayan N, Clarke AE, Keeling S, et al. Monitoring of systemic lupus erythematosus pregnancies: A systematic literature review. J Rheumatol. 2018;45(10):1477-1490. doi: 10.3899/jrheum.171023

51. Colquhoun M, Thanopoulou V, Quick V, Mouyis M. Rituximab administration during the second trimester of pregnancy for systemic lupus erythematosus: Case report and review of the literature on rheumatic disease. Mod Rheumatol Case Rep. 2022;6(2):173- 177. doi: 10.1093/mrcr/rxab051

52. Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res (Hoboken). 2023;75(3):449-464. doi: 10.1002/acr.25045

53. Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882

54. Белов БС, Соловьев СК, Тарасова ГМ, Асеева ЕА. Вакцинация у больных системной красной волчанкой: результаты и перспективы. Научно-практическая ревматология. 2018;56(3):373-379. doi: 10.14412/1995-4484-2018-373-379

55. Насонов ЕЛ, Румянцев АГ, Самсонов МЮ. Фармакотерапия аутоиммунных ревматических заболеваний – от моноклональных антител к CAR-T-клеткам: 20 лет спустя. Научно-практическая ревматология. 2024;62(3):262-279. doi: 10.47360/1995-4484-2024-262-279